Search - tctmd.com

Displaying 261 - 280 of 400

Sort: Relevancy | Date

News Conference News AHA 2019

Early Data Favorable for New RNAi Therapies to Reduce Triglycerides

Caitlin E. Cox

November 19, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

Michael O'Riordan

November 11, 2019

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

Shelley Wood

November 11, 2019

News Daily News

Noninvasive Tests for Chest Pain: New Insight Into Who Benefits Most

Yael L. Maxwell

November 07, 2019

News Daily News

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Michael O'Riordan

November 05, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2019

Todd Neale

October 31, 2019

News Daily News

Gaps in Access to TAVR and SAVR: ‘Something Needs to Be Done’

L.A. McKeown

October 29, 2019

News Daily News

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Michael O'Riordan

October 22, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Conference News TCT 2019

Tailored Hydration Strategy Cuts Contrast-Induced Kidney Injury: REMEDIAL III

Michael O'Riordan

October 03, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Conference News ESC 2019

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Yael L. Maxwell

August 31, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Opinion Off Script

#Selfies, Carrots, and Push-ups: A Defense of Social Media in Modern-Day Medicine

Mamas Mamas, BMBCh

August 23, 2019

News Opinion Conversations in Cardiology

Conversations in Cardiology: The Push for High-Sensitivity Troponin

August 02, 2019

News Conference News SCCT 2019

CTA or Function Tests in High-risk Chest Pain and No Known CAD: Debate Goes On

Yael L. Maxwell

July 16, 2019

News Daily News

Clopidogrel-Aspirin in Minor Stroke/TIA of Maximum Benefit in First 21 Days

Todd Neale

July 09, 2019

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

Todd Neale

June 26, 2019

Advertisement

Early Data Favorable for New RNAi Therapies to Reduce Triglycerides

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

Noninvasive Tests for Chest Pain: New Insight Into Who Benefits Most

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

TCTMD’s Top 10 Most Popular Stories for October 2019

Gaps in Access to TAVR and SAVR: ‘Something Needs to Be Done’

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Recurrent Events Common Among Young Patients With CAD

Tailored Hydration Strategy Cuts Contrast-Induced Kidney Injury: REMEDIAL III

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

#Selfies, Carrots, and Push-ups: A Defense of Social Media in Modern-Day Medicine

Conversations in Cardiology: The Push for High-Sensitivity Troponin

CTA or Function Tests in High-risk Chest Pain and No Known CAD: Debate Goes On

Clopidogrel-Aspirin in Minor Stroke/TIA of Maximum Benefit in First 21 Days

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content